Healthcare
Haleon plc(HLNCF)
Live Price
Offline$4.45
+4.81% today
1Y Change
-18.29%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $30.25B
- Revenue Growth
- -1.8%
- EPS Growth
- +18.8%
- Dividend Yield
- 2.1%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Haleon plc (HLNCF) is a Healthcare stock with a market cap of $30.25B and listed on OTC. The stock last traded around $4.45 and down 18.3% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -1.8%, EPS growth of +18.8%, a dividend yield of 2.1%. What stands out right now is revenue -1.8%, EPS +18.8%, free cash flow +1.6% with operating margin 18.8% and ROIC 4.1%. The dividend is present but secondary, with a yield around 2.1%. Valuation is more restrained than many high-expectation growth names at P/E 29.7 and price/sales 3.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines HLNCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.8% vs +7.6% peer median
Operating Margin
Near sector median
+18.8% vs +19.4% peer median
P/E
Below sector median
29.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 25, 2026 with an EPS surprise of +2.9% and a revenue surprise of -1.3%.
The operating picture looks softer than before
Revenue is at -1.8% and EPS is at +18.8%, with operating margin around 18.8%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 25, 2026 | +2.9% | +2.4% | +3.0% | -7.6% |
2025 Jul 31, 2025 | -51.0% | -4.1% | -3.7% | -0.6% |
2025 May 8, 2025 | โ | -2.3% | -0.4% | -6.2% |
Benchmark Edge
HLNCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HLNCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HLNCF Max Drawdown
-25.39%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HLNCF and SPY.
Company Overview
Haleon plc
Other OTC
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
- Leadership
- Brian James McNamara
- IPO Date
- Jul 28, 2022
- Employees
- 24.6k
- Street Address
- Building 5
- Mailing
- Weybridge, KT13 0NY
- Region
- Weybridge, GB
- Reporting Currency
- USD
- Investor Line
- 44 1932 822000
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.7
- EV/EBITDA
- 18.1
- Price/Sales
- 3.7
- Price/Book
- 1.9
Growth
- Revenue
- -1.8%
- EPS
- +18.8%
- Free Cash Flow
- +1.6%
Profitability
- Gross Margin
- 61.5%
- Operating Margin
- 18.8%
- Net Margin
- 12.6%
- ROE
- 6.4%
- ROIC
- 4.1%
Balance Sheet
- Debt/Equity
- 0.52
- Current Ratio
- 0.92
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.